新生儿甲状腺功能亢进症筛查的概念验证
本研究基于法国2007-2014年数据,评估用出生后第3天滤纸干血促甲状腺激素值筛查新生儿甲状腺功能亢进症的可行性。回顾性病例对照研究显示,筛查促甲状腺激素低于0.18 mIU/L对检出重度新生儿甲状腺功能亢进症的灵敏度为71%(95%CI 44-90%),特异度为99%(95%CI 99-100%)。作者认为该筛查试验可用于检出重度新生儿甲状腺功能亢进症,最佳切点为0.18 mIU/L。
要点
- 出生后第3天筛查促甲状腺激素低于0.18 mIU/L检出重度新生儿甲状腺功能亢进症的灵敏度为71%(95%CI 44-90%),特异度为99%(95%CI 99-100%)。
- 筛查促甲状腺激素值是新生儿甲状腺功能亢进症最强预测因子(P < .00001),受试者工作特征曲线下面积为0.98(95%CI 0.95-1.0)。
- 作者认为该筛查试验可用于检出重度新生儿甲状腺功能亢进症,最佳切点为0.18 mIU/L。
核心结论
- 筛查促甲状腺激素试验可用于检出重度新生儿甲状腺功能亢进症,最佳切点为0.18 mIU/L。
- 与先天性甲状腺功能减退症筛查相比,额外成本较小。
- 新生儿甲状腺功能亢进症患儿在许多情况下可在症状前阶段得到更早诊断并开始治疗,从而确保最佳结局。
研究设计与样本
- 回顾性病例对照研究。
- 病例来自先前发表的法国10个产科单位2007-2014年出生的280 000名婴儿研究数据。
- 对照来自同期法兰西岛地区出生的1 362 564名婴儿。
- 评估出生后第3天常规采集于滤纸上的干血促甲状腺激素值用于新生儿甲状腺功能亢进症筛查的可行性。
主要发现
- 出生后第3天筛查促甲状腺激素低于0.18 mIU/L检出重度新生儿甲状腺功能亢进症的灵敏度为71%(95%CI 44-90%),特异度为99%(95%CI 99-100%),阳性预测值为81%(95%CI 74-86%),阴性预测值为98%(95%CI 97-99%)。
- 单因素回归分析显示,筛查促甲状腺激素值是新生儿甲状腺功能亢进症最强预测因子(P < .00001),受试者工作特征曲线下面积为0.98(95%CI 0.95-1.0)。
- 预期频率与观察频率无显著差异(Hosmer-Lemeshow检验,P = .99)。
关键数值与推荐
- 筛查促甲状腺激素低于0.18 mIU/L用于检出重度新生儿甲状腺功能亢进症:灵敏度71%(95%CI 44-90%),特异度99%(95%CI 99-100%),阳性预测值81%(95%CI 74-86%),阴性预测值98%(95%CI 97-99%)。
- 筛查促甲状腺激素值预测新生儿甲状腺功能亢进症的受试者工作特征曲线下面积为0.98(95%CI 0.95-1.0),P < .00001。
- Hosmer-Lemeshow检验P = .99。
临床怎么用
- 作者认为筛查促甲状腺激素试验可用于检出重度新生儿甲状腺功能亢进症,最佳切点为0.18 mIU/L。
- 作者认为与先天性甲状腺功能减退症筛查相比额外成本较小。
- 作者认为新生儿甲状腺功能亢进症患儿在许多情况下可在症状前阶段得到更早诊断并开始治疗,从而确保最佳结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Early treatment is essential to avoid the cardiac complication of neonatal hyperthyroidism (NH). Our results have direct implications for clinical care. OBJECTIVE: NH can cause potentially fatal neonatal thyrotoxicosis. Here, we have evaluated the feasibility of neonatal hyperthyroidism screening using the thyroid-stimulating hormone value in dried blood collected routinely on filter paper on the third postnatal day of life for congenital hypothyroidism screening. METHODS: Retrospective case-control study. Cases were identified using data from our previously published study of 280 000 infants born in 10 maternity units in France in 2007-2014. Controls were identified among the 1 362 564 infants born in the Ile-de-France region during the same period. RESULTS: A screening thyroid-stimulating hormone level below 0.18 mIU/L on the third postnatal day had 71% (95% CI 44-90%) sensitivity, 99% (95% CI 99-100%) specificity, 81% (95% CI 74-86%) positive predictive value, and 98% (95% CI 97-99%) negative predictive value for detecting severe NH. By univariate regression analysis, the screening thyroid-stimulating hormone value was the strongest predictor of NH (P < .00001), with an area under the receiver-operating characteristics curve of 0.98 (95% CI 0.95-1.0). Expected frequencies were not significantly different from observed frequencies (Hosmer-Lemeshow test, P = .99). CONCLUSION: The screening thyroid-stimulating hormone test can be used to detect severe NH, the optimal cut-off being 0.18 mIU/L. The additional cost compared with screening for congenital hypothyroidism would be small. Infants with neonatal hyperthyroidism would benefit from an earlier diagnosis with treatment initiation at the presymptomatic stage in many cases, ensuring optimal outcomes.
引用
- Banigé M, Kariyawasam D, Gauthereau V, et al. Neonatal Screening for Hyperthyroidism Proof of Concept. J Clin Endocrinol Metab. 2022. PMID: 34894265. doi:10.1210/clinem/dgab890
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。